- Country: Poland
- Summary: Repackaging and Blinding of Drugs with the Active Substance Pirfenidone and Nintedanib
- PLT Ref No: 95015623
- Deadline: 08 Feb 2024
- Financier: Self Financed
- Purchaser Ownership: Government
- Tender Value: Refer Document
- Notice Type: Tender
- Document Ref. No.: 16936-2024
- Purchaser's Detail:Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
- Description:
- The subject of the order is the repackaging and blinding of drugs with the active substance pirfenidone and nintedanib (the drugs are provided by the ordering party) as well as the production, packaging and delivery of placebo (for both original products). Coding of products (drugs and placebo) for the study entitled "Double blindOne randomized clinical trial comparing the effectiveness of 52 weeks of pirfenidone therapy to nintedanib and standard therapy with mycophenolate mofetil in patients with interstitial lung disease in the course of systemic connective tissue diseases (CTD-ILD) and hypersensitivity disease (HP)."Pproject financed by the Medical Research Agency (Co-financing agreement No. 2022 ABM-03-00009 -00). A detailed description of the subject of the order is included in this SWZ and:
1) Annex No. 2 - description of the subject of the order
2) Annex No. 3 - draft contract,
Repackaging and blinding of active substance drugspirfenidone and nintedanib
Repackaging and blinding of drugs with the active substance pirfenidone and nintedanib (the drugs are provided by the ordering party) and the production, packaging and delivery of placebo (for both original products). Coding of products (drugs and placebo) for the study entitled "Double-slideepione, a randomized clinical trial comparing the effectiveness of 52 weeks of pirfenidone therapy to nintedanib and standard therapy with mycophenolate mofetil in patients with interstitial lung disease in the course of systemic connective tissue diseases (CTD-ILD) and hypersensitivity disease (HP)
... - Documents:
If you are registered member, kindly login to view full details of this tender notice:
CLICK HERE TO LOGINRepackaging and Blinding of Drugs with the Active Substance Pirfenidone and Nintedanib - Poland Tender
The NATIONAL INSTITUTE OF GERIATRICS, RHEUMATOLOGY AND REHABILITATION PROF. PH.D. MED. ELEONORA REICHER, a Government sector organization in Poland, has announced a new tender for Repackaging and Blinding of Drugs with the Active Substance Pirfenidone and Nintedanib. This tender is published on PolandTenders under PLT Ref No: 95015623 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2024-02-08.
The estimated tender value is Refer Document, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.
